Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA3 | O75311 | 1/20 | 0.48 |
| ▸ | GLRB | P48167 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | LDHB | P07195 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116615 | 0.91 | GLRA3 (0.51) | GLRA3GLRBSRD5A2TDP1EPHX2 | |
| SCHEMBL4127543 | 0.87 | GLRA3 (0.50) | GLRA3GLRBSRD5A2BCL2L1TDP1 | |
| SCHEMBL4122437 | 0.87 | GLRA3 (0.53) | GLRA3GLRBSRD5A2TDP1LDHA | |
| SCHEMBL4113584 | 0.85 | GLRA3 (0.54) | GLRA3GLRBBCL2L1CYP2C8AKR1C3 | |
| SCHEMBL4115756 | 0.85 | GLRA3 (0.50) | GLRA3GLRBSRD5A2TDP1NPC1 | |
| SCHEMBL4122728 | 0.84 | GLRA3 (0.44) | GLRA3GLRBEPHX2DHODHNPC1 | |
| SCHEMBL4126309 | 0.80 | GLRA3 (0.48) | GLRA3GLRBSRD5A2TDP1IGFBP3 | |
| SCHEMBL4120741 | 0.80 | GLRA3 (0.48) | GLRA3GLRBBCL2L1LTC4SSMN1; SMN2 | |
| SCHEMBL4116563 | 0.80 | GLRA3 (0.44) | GLRA3GLRBSRD5A2SMN1; SMN2AKR1C2 | |
| SCHEMBL4128153 | 0.77 | GLRA3 (0.44) | GLRA3GLRBSRD5A2TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| EP-1890993-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | claimed |
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| EP-1890993-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | GLRA1, GLRB, GPBAR1 | GLRA3 6/4885GLRB 2/4885SRD5A2 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.